Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 22Unknown 11Recruiting 11Terminated 3Not yet recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 98Lymphoid 8Thoracic 6Tumor-Agnostic 4Gynecologic 4Head & Neck 3Genitourinary 3Other solid neoplasm 1Other hematologic neoplasm 1NET 1Endocrine 1Dermatologic 1Breast 1

Conditions

Advanced Solid Tumors 1

Interventions

pembrolizumab 27Nivolumab 11Pemetrexed 10Cyclophosphamide 10Carboplatin 10atezolizumab 9Specimen Handling 8Cisplatin 8Ipilimumab 6Biopsy 6Injections 5tislelizumab 4spartalizumab 4fludarabine 4Vincristine 4Radiotherapy 4Proton Therapy 4Platinum 4Paclitaxel 4Drug Therapy 4Docetaxel 4Bevacizumab 41,2-diaminocyclohexaneplatinum II citrate 4durvalumab 3Trastuzumab 3Etoposide 3Cetuximab 3zimberelimab 2trametinib 2tocilizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Oxaliplatin × Other solid neoplasm × Clear all
NCT05083481 2026-05-05

A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors

Astellas Pharma Inc

Phase 1/2 Active not recruiting
226 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡